Also, symbol ARQL. NIH confirmed efficacy and safety for liver, prostate, uterine cancers. Most researched and tested molecule in industry so Novartis will acquire this company without a doubt and it's a matter of when now. Based on rev projection on approval of drug would be $18-21/share within 2 years. That's an extreme opportunity. See the list of continued insider buys and very savvy purchases via SC-13G filings.